[Intraabdominal administration of MMC adsorbed on activated carbon for management of carcinomatous peritonitis]

Abstract

When Mitomycin C, adsorbed on to activated carbon particles (MMC-CH) was administered intraperitoneally, it was absorbed well by the omentum and peritoneum, and eventually by the lymphatic system. MMC-CH yielded high drug concentrations in intraabdominal tissues and exhibited remarkably low levels in extra-abdominal tissues and peripheral blood. We conducted clinical trials with MMC-CH in 26 patients with carcinomatous peritonitis. High MMC concentrations persisted in ascites, while drug concentrations were extremely low in peripheral blood. Eighteen of the 26 patients studied responded well to MMC-CH and were able to tolerate about 5 times the conventional dose of MMC. Serious adverse effects were not observed, despite the administration of such a large dose.